Abstract
Systemic lupus erythematosus (SLE) is a multifactorial disorder with multigenic inheritance and various environmental factors implicated in its aetiopathogenesis. Despite the multiple mechanisms involved in the aetiology of SLE being elusive, recent studies have made progress in our understanding of the pathogenic mechanisms via abnormal regulation of cell-mediated and humoral immunity that lead to tissue damage. The heterogeneity of the clinical manifestations probably reflects the complexity of the disease pathogenesis itself. The immune system in SLE is characterised by a complex interplay between overactive B cells, abnormally activated T cells and antigen-presenting cells. This interplay leads to the production of an array of inflammatory cytokines, apoptotic cells, diverse autoantibodies and immune complexes that in turn activate effector cells and the complement system, leading to tissue injury and damage which are the hallmarks of the clinical manifestations. SLE patients have dysregulation of inflammatory cytokines, chemokines and immune response-related genes, as well as of the genes involved in apoptosis, signal transduction and the cell cycle.
Similar content being viewed by others
References
Kyttaris VC, Katsiari CG, Juang YT, Tsokos GC (2005) New insights into the pathogenesis of systemic lupus erythematosus. Curr Rheumatol Rep 7:469–475
Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349:1526–1533
Demirci FY, Manzi S, Ramsey-Goldman R, Kenney M, Shaw PS, Dunlop-Thomas CM, Kao AH, Rhew EY, Bontempo F, Kammerer C, Kamboh MI (2007) Association study of Toll-like receptor 5 (TLR5) and Toll-like receptor 9 (TLR9) polymorphisms in systemic lupus erythematosus. J Rheumatol 34:1708–1711
Sanchez E, Callejas-Rubio JL, Sabio JM, Gonzalez-Gay MA, Jimenez-Alonso J, Mico L, de Ramon E, Camps M, Suarez A, Gutierrez C, Garcia-Portales R, Tolosa C, Ortego-Centeno N, Sanchez-Roman J, Garcia-Hernandez FJ, Gonzalez-Escribano MF, Martin J (2009) Investigation of TLR5 and TLR7 as candidate genes for susceptibility to systemic lupus erythematosus. Clin Exp Rheumatol 27:267–271
Hochberg MC (1987) Prevalence of systemic lupus erythematosus in England and Wales, 1981–2. Ann Rheum Dis 46:664–666
Deapen D, Escalante A, Weinrib L, Horwitz D, Bachman B, Roy-Burman P, Walker A, Mack TM (1992) A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 35:311–318
Kelly JA, Moser KL, Harley JB (2002) The genetics of systemic lupus erythematosus: putting the pieces together. Genes Immun 3(Suppl 1):S71–S85
Manderson AP, Botto M, Walport MJ (2004) The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 22:431–456
Tsao BP (2003) The genetics of human systemic lupus erythematosus. Trends Immunol 24:595–602
Harley JB, Alarcon-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, Tsao BP, Vyse TJ, Langefeld CD, Nath SK, Guthridge JM, Cobb BL, Mirel DB, Marion MC, Williams AH, Divers J, Wang W, Frank SG, Namjou B, Gabriel SB, Lee AT, Gregersen PK, Behrens TW, Taylor KE, Fernando M, Zidovetzki R, Gaffney PM, Edberg JC, Rioux JD, Ojwang JO, James JA, Merrill JT, Gilkeson GS, Seldin MF, Yin H, Baechler EC, Li QZ, Wakeland EK, Bruner GR, Kaufman KM, Kelly JA (2008) Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 40:204–210
Jarvinen TM, Hellquist A, Zucchelli M, Koskenmies S, Panelius J, Hasan T, Julkunen H, D'Amato M, Kere J (2011) Replication of genome-wide association study identified systemic lupus erythematosus susceptibility genes affirms B-cell receptor pathway signalling and strengthens the role of IRF5 in disease susceptibility in a Northern European population. Rheumatology (Oxford). doi:10.1093/rheumatology/ker263
Zhou XJ, Lu XL, Nath SK, Lv JC, Zhu SN, Yang HZ, Qin LX, Zhao MH, Su Y, Shen N, Li ZG, Zhang H (2011) Gene–gene interaction of BLK, TNFSF4, TRAF1, TNFAIP3. REL in systemic lupus erythematosus. Arthritis Rheum. doi:10.1002/art.33318
Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ (2000) Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 76:227–324
Seelen MA, Trouw LA, Daha MR (2003) Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. Curr Opin Nephrol Hypertens 12:619–624
Trouw LA, Groeneveld TW, Seelen MA, Duijs JM, Bajema IM, Prins FA, Kishore U, Salant DJ, Verbeek JS, van Kooten C, Daha MR (2004) Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 114:679–688
Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR, Lipsky PE, Radbruch A, Dorner T (2000) Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 165:5970–5979
Tangye SG, Liu YJ, Aversa G, Phillips JH, de Vries JE (1998) Identification of functional human splenic memory B cells by expression of CD148 and CD27. J Exp Med 188:1691–1703
Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA (2002) An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46:2673–2677
Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA (2005) B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 44:1542–1545
Shlomchik MJ, Craft JE, Mamula MJ (2001) From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 1:147–153
Tsokos GC, Nambiar MP, Tenbrock K, Juang YT (2003) Rewiring the T-cell: signaling defects and novel prospects for the treatment of SLE. Trends Immunol 24:259–263
Tsokos GC, Mitchell JP, Juang YT (2003) T cell abnormalities in human and mouse lupus: intrinsic and extrinsic. Curr Opin Rheumatol 15:542–547
Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klareskog L, Lundberg I (2000) Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 18:565–570
Casciola-Rosen L, Andrade F, Ulanet D, Wong WB, Rosen A (1999) Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med 190:815–826
Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL (2001) Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 159:237–243
Cooper GS, Parks CG (2004) Occupational and environmental exposures as risk factors for systemic lupus erythematosus. Curr Rheumatol Rep 6:367–374
Incaprera M, Rindi L, Bazzichi A, Garzelli C (1998) Potential role of the Epstein–Barr virus in systemic lupus erythematosus autoimmunity. Clin Exp Rheumatol 16:289–294
Moon UY, Park SJ, Oh ST, Kim WU, Park SH, Lee SH, Cho CS, Kim HY, Lee WK, Lee SK (2004) Patients with systemic lupus erythematosus have abnormally elevated Epstein–Barr virus load in blood. Arthritis Res Ther 6:R295–R302
James JA, Neas BR, Moser KL, Hall T, Bruner GR, Sestak AL, Harley JB (2001) Systemic lupus erythematosus in adults is associated with previous Epstein–Barr virus exposure. Arthritis Rheum 44:1122–1126
Crow MK (2003) Interferon-alpha: a new target for therapy in systemic lupus erythematosus? Arthritis Rheum 48:2396–2401
Anders HJ, Banas B, Schlondorff D (2004) Signaling danger: toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 15:854–867
Brummel R, Lenert P (2005) Activation of marginal zone B cells from lupus mice with type A(D) CpG-oligodeoxynucleotides. J Immunol 174:2429–2434
Gilkeson GS, Pippen AM, Pisetsky DS (1995) Induction of cross-reactive anti-dsDNA antibodies in preautoimmune NZB/NZW mice by immunization with bacterial DNA. J Clin Invest 95:1398–1402
Hasegawa K, Hayashi T (2003) Synthetic CpG oligodeoxynucleotides accelerate the development of lupus nephritis during preactive phase in NZB × NZWF1 mice. Lupus 12:838–845
Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A (2002) Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416:603–607
Lenert P, Goeken A, Handwerger BS, Ashman RF (2003) Innate immune responses in lupus-prone Palmerston North mice: differential responses to LPS and bacterial DNA/CpG oligonucleotides. J Clin Immunol 23:202–213
Cline AM, Radic MZ (2004) Murine lupus autoantibodies identify distinct subsets of apoptotic bodies. Autoimmunity 37:85–93
Cline AM, Radic MZ (2004) Apoptosis, subcellular particles, and autoimmunity. Clin Immunol 112:175–182
Cocca BA, Cline AM, Radic MZ (2002) Blebs and apoptotic bodies are B cell autoantigens. J Immunol 169:159–166
Laderach D, Koutouzov S, Bach JF, Yamamoto AM (2003) Concomitant early appearance of anti-ribonucleoprotein and anti-nucleosome antibodies in lupus prone mice. J Autoimmun 20:161–170
Lorenz HM, Herrmann M, Winkler T, Gaipl U, Kalden JR (2000) Role of apoptosis in autoimmunity. Apoptosis 5:443–449
Malmegrim KC, Pruijn GJ, van Venrooij WJ (2002) The fate of the U1 snRNP autoantigen during apoptosis: implications for systemic autoimmunity. Isr Med Assoc J 4:706–712
Ohlsson M, Jonsson R, Brokstad KA (2002) Subcellular redistribution and surface exposure of the Ro52, Ro60 and La48 autoantigens during apoptosis in human ductal epithelial cells: a possible mechanism in the pathogenesis of Sjögren's syndrome. Scand J Immunol 56:456–469
Purcell AW, Todd A, Kinoshita G, Lynch TA, Keech CL, Gething MJ, Gordon TP (2003) Association of stress proteins with autoantigens: a possible mechanism for triggering autoimmunity? Clin Exp Immunol 132:193–200
Rosen A, Casciola-Rosen L (1999) Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. Cell Death Differ 6:6–12
Tran HB, Ohlsson M, Beroukas D, Hiscock J, Bradley J, Buyon JP, Gordon TP (2002) Subcellular redistribution of la/SSB autoantigen during physiologic apoptosis in the fetal mouse heart and conduction system: a clue to the pathogenesis of congenital heart block. Arthritis Rheum 46:202–208
Tran HB, Macardle PJ, Hiscock J, Cavill D, Bradley J, Buyon JP, Gordon TP (2002) Anti-La/SSB antibodies transported across the placenta bind apoptotic cells in fetal organs targeted in neonatal lupus. Arthritis Rheum 46:1572–1579
Nossent JC, Henzen-Logmans SC, Vroom TM, Huysen V, Berden JH, Swaak AJ (1991) Relation between serological data at the time of biopsy and renal histology in lupus nephritis. Rheumatol Int 11:77–82
Norsworthy P, Theodoridis E, Botto M, Athanassiou P, Beynon H, Gordon C, Isenberg D, Walport MJ, Davies KA (1999) Overrepresentation of the Fcgamma receptor type IIA R131/R131 genotype in caucasoid systemic lupus erythematosus patients with autoantibodies to C1q and glomerulonephritis. Arthritis Rheum 42:1828–1832
Coremans IE, Daha MR, van der Voort EA, Siegert CE, Breedveld FC (1995) Subclass distribution of IgA and IgG antibodies against Clq in patients with rheumatic diseases. Scand J Immunol 41:391–397
Coremans IE, Spronk PE, Bootsma H, Daha MR, van der Voort EA, Kater L, Breedveld FC, Kallenberg CG (1995) Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am J Kidney Dis 26:595–601
Moroni G, Trendelenburg M, Del Papa N, Quaglini S, Raschi E, Panzeri P, Testoni C, Tincani A, Banfi G, Balestrieri G, Schifferli JA, Meroni PL, Ponticelli C (2001) Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 37:490–498
Mannik M, Wener MH (1997) Deposition of antibodies to the collagen-like region of C1q in renal glomeruli of patients with proliferative lupus glomerulonephritis. Arthritis Rheum 40:1504–1511
Holers VM (2004) Anti-C1q autoantibodies amplify pathogenic complement activation in systemic lupus erythematosus. J Clin Invest 114:616–619
Okamura M, Kanayama Y, Amastu K, Negoro N, Kohda S, Takeda T, Inoue T (1993) Significance of enzyme linked immunosorbent assay (ELISA) for antibodies to double stranded and single stranded DNA in patients with lupus nephritis: correlation with severity of renal histology. Ann Rheum Dis 52:14–20
Bosma GC, Oshinsky J, Kiefer K, Nakajima PB, Charan D, Congelton C, Radic M, Bosma MJ (2006) Development of functional B cells in a line of SCID mice with transgenes coding for anti-double-stranded DNA antibody. J Immunol 176:889–898
Ravirajan CT, Rahman MA, Papadaki L, Griffiths MH, Kalsi J, Martin AC, Ehrenstein MR, Latchman DS, Isenberg DA (1998) Genetic, structural and functional properties of an IgG DNA-binding monoclonal antibody from a lupus patient with nephritis. Eur J Immunol 28:339–350
Mason LJ, Ravirajan CT, Latchman DS, Isenberg DA (2001) A human anti-dsDNA monoclonal antibody caused hyaline thrombi formation in kidneys of ‘leaky’ SCID mice. Clin Exp Immunol 126:137–142
Bave U, Alm GV, Ronnblom L (2000) The combination of apoptotic U937 cells and lupus IgG is a potent IFN-alpha inducer. J Immunol 165:3519–3526
Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418:191–195
Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z, Punaro M, Baisch J, Guiducci C, Coffman RL, Barrat FJ, Banchereau J, Pascual V (2011) Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 3:73ra20
Kaplan MJ (2011) Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol 7:691–6990
Wellmann U, Letz M, Herrmann M, Angermuller S, Kalden JR, Winkler TH (2005) The evolution of human anti-double-stranded DNA autoantibodies. Proc Natl Acad Sci USA 102:9258–9263
Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD (2008) Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum 58:2470–2480
Duzgun N, Hoier-Madsen M, Wiik A, Tokgoz G (1997) The frequency of autoantibodies in Turkish patients with lupus nephritis. Rheumatol Int 17:1–4
Minota S, Yoshio T, Iwamoto M, Takeda A, Masuyama J, Mimori A, Yamada A, Kano S (1996) Selective accumulation of anti-histone antibodies in glomeruli of lupus-prone lpr mice. Clin Immunol Immunopathol 80:82–87
Elouaai F, Lule J, Benoist H, Appolinaire-Pilipenko S, Atanassov C, Muller S, Fournie GJ (1994) Autoimmunity to histones, ubiquitin, and ubiquitinated histone H2A in NZB x NZW and MRL-lpr/lpr mice. Anti-histone antibodies are concentrated in glomerular eluates of lupus mice. Nephrol Dial Transplant 9:362–366
Van Bruggen MC, Kramers C, Berden JH (1996) Autoimmunity against nucleosomes and lupus nephritis. Ann Med Interne (Paris) 147:485–489
Amoura Z, Piette JC, Bach JF, Koutouzov S (1999) The key role of nucleosomes in lupus. Arthritis Rheum 42:833–843
Burlingame RW, Boey ML, Starkebaum G, Rubin RL (1994) The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest 94:184–192
Massa M, De Benedetti F, Pignatti P, Albani S, Di Fuccia G, Monestier M, Martini A (1994) Anti-double stranded DNA, anti-histone, and anti-nucleosome IgG reactivities in children with systemic lupus erythematosus. Clin Exp Rheumatol 12:219–225
Amoura Z, Chabre H, Koutouzov S, Lotton C, Cabrespines A, Bach JF, Jacob L (1994) Nucleosome-restricted antibodies are detected before anti-dsDNA and/or antihistone antibodies in serum of MRL-Mp lpr/lpr and +/+ mice, and are present in kidney eluates of lupus mice with proteinuria. Arthritis Rheum 37:1684–1688
Kramers C, Hylkema MN, Van Bruggen MC, van de Lagemaat R, Dijkman HB, Assmann KJ, Smeenk RJ, Berden JH (1994) Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest 94:568–577
Schmiedeke T, Stoeckl F, Muller S, Sugisaki Y, Batsford S, Woitas R, Vogt A (1992) Glomerular immune deposits in murine lupus models may contain histones. Clin Exp Immunol 90:453–458
Stockl F, Schmiedeke T, Batsford S, Vogt A (1992) Histone-mediated DNA binding in lupus nephritis. Arthritis Rheum 35:367–368
Van Bruggen MC, Kramers K, Hylkema MN, van den Born J, Bakker MA, Assmann KJ, Smeenk RJ, Berden JH (1995) Decrease of heparan sulfate staining in the glomerular basement membrane in murine lupus nephritis. Am J Pathol 146:753–763
Rumore PM, Steinman CR (1990) Endogenous circulating DNA in systemic lupus erythematosus. Occurrence as multimeric complexes bound to histone. J Clin Invest 86:69–74
Licht R, Van Bruggen MC, Oppers-Walgreen B, Rijke TP, Berden JH (2001) Plasma levels of nucleosomes and nucleosome-autoantibody complexes in murine lupus: effects of disease progression and lipopolyssacharide administration. Arthritis Rheum 44:1320–1330
Williams RC Jr, Malone CC, Meyers C, Decker P, Muller S (2001) Detection of nucleosome particles in serum and plasma from patients with systemic lupus erythematosus using monoclonal antibody 4H7. J Rheumatol 28:81–94
Burlingame RW, Rubin RL, Balderas RS, Theofilopoulos AN (1993) Genesis and evolution of antichromatin autoantibodies in murine lupus implicates T-dependent immunization with self antigen. J Clin Invest 91:1687–1696
Lu Q, Kanai Y, Kubota T (2003) The emergence of anti-dsDNA antibodies precedes nucleosome-specific antibodies in MRL/lpr and MRL/+ mice. J Med Dent Sci 50:9–15
Meziere C, Stockl F, Batsford S, Vogt A, Muller S (1994) Antibodies to DNA, chromatin core particles and histones in mice with graft-versus-host disease and their involvement in glomerular injury. Clin Exp Immunol 98:287–294
Sato S, Kodera M, Hasegawa M, Fujimoto M, Takehara K (2004) Antinucleosome antibody is a major autoantibody in localized scleroderma. Br J Dermatol 151:1182–1188
Suer W, Dahnrich C, Schlumberger W, Stocker W (2004) Autoantibodies in SLE but not in scleroderma react with protein-stripped nucleosomes. J Autoimmun 22:325–334
Radic M, Marion T, Monestier M (2004) Nucleosomes are exposed at the cell surface in apoptosis. J Immunol 172:6692–6700
Kaliyaperumal A, Michaels MA, Datta SK (2002) Naturally processed chromatin peptides reveal a major autoepitope that primes pathogenic T and B cells of lupus. J Immunol 168:2530–2537
Lu L, Kaliyaperumal A, Boumpas DT, Datta SK (1999) Major peptide autoepitopes for nucleosome-specific T cells of human lupus. J Clin Invest 104:345–355
Fournel S, Neichel S, Dali H, Farci S, Maillere B, Briand JP, Muller S (2003) CD4+ T cells from (New Zealand Black x New Zealand White)F1 lupus mice and normal mice immunized against apoptotic nucleosomes recognize similar Th cell epitopes in the C terminus of histone H3. J Immunol 171:636–644
Kaliyaperumal A, Mohan C, Wu W, Datta SK (1996) Nucleosomal peptide epitopes for nephritis-inducing T helper cells of murine lupus. J Exp Med 183:2459–2469
Suen JL, Chuang YH, Tsai BY, Yau PM, Chiang BL (2004) Treatment of murine lupus using nucleosomal T cell epitopes identified by bone marrow-derived dendritic cells. Arthritis Rheum 50:3250–3259
Kaliyaperumal A, Michaels MA, Datta SK (1999) Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells. J Immunol 162:5775–5783
Bonfa E, Elkon KB (1986) Clinical and serologic associations of the antiribosomal P protein antibody. Arthritis Rheum 29:981–985
Bonfa E, Golombek SJ, Kaufman LD, Skelly S, Weissbach H, Brot N, Elkon KB (1987) Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 317:265–271
Isshi K, Hirohata S (1996) Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 39:1483–1490
Schneebaum AB, Singleton JD, West SG, Blodgett JK, Allen LG, Cheronis JC, Kotzin BL (1991) Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med 90:54–62
Tzioufas AG, Tzortzakis NG, Panou-Pomonis E, Boki KA, Sakarellos-Daitsiotis M, Sakarellos C, Moutsopoulos HM (2000) The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease. Ann Rheum Dis 59:99–104
Watanabe T, Sato T, Uchiumi T, Arakawa M (1996) Neuropsychiatric manifestations in patients with systemic lupus erythematosus: diagnostic and predictive value of longitudinal examination of anti-ribosomal P antibody. Lupus 5:178–183
Yoshio T, Hirata D, Onda K, Nara H, Minota S (2005) Antiribosomal P protein antibodies in cerebrospinal fluid are associated with neuropsychiatric systemic lupus erythematosus. J Rheumatol 32:34–39
Derksen RH, van Dam AP, Gmelig Meyling FH, Bijlsma JW, Smeenk RJ (1990) A prospective study on antiribosomal P proteins in two cases of familial lupus and recurrent psychosis. Ann Rheum Dis 49:779–782
Gerli R, Caponi L, Tincani A, Scorza R, Sabbadini MG, Danieli MG, De Angelis V, Cesarotti M, Piccirilli M, Quartesan R, Moretti P, Cantoni C, Franceschini F, Cavazzana I, Origgi L, Vanoli M, Bozzolo E, Ferrario L, Padovani A, Gambini O, Vanzulli L, Croce D, Bombardieri S (2002) Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford) 41:1357–1366
Ghirardello A, Doria A, Zampieri S, Gerli R, Rapizzi E, Gambari PF (2000) Anti-ribosomal P protein antibodies detected by immunoblotting in patients with connective tissue diseases: their specificity for SLE and association with IgG anticardiolipin antibodies. Ann Rheum Dis 59:975–981
Chindalore V, Neas B, Reichlin M (1998) The association between anti-ribosomal P antibodies and active nephritis in systemic lupus erythematosus. Clin Immunol Immunopathol 87:292–296
Grunebaum E, Blank M, Cohen S, Afek A, Kopolovic J, Meroni PL, Youinou P, Shoenfeld Y (2002) The role of anti-endothelial cell antibodies in Kawasaki disease—in vitro and in vivo studies. Clin Exp Immunol 130:233–240
Tseng JC, Lu LY, Hu RJ, Kau CK, Cheng HH, Lin PR, Sun CW, Liang HT, Lam HC, Tai MH (2007) Elevated serum anti-endothelial cell autoantibodies titer is associated with lupus nephritis in patients with systemic lupus erythematosus. J Microbiol Immunol Infect 40:50–55
Aringer M, Smolen JS (2005) Cytokine expression in lupus kidneys. Lupus 14:13–18
Scuderi F, Convertino R, Molino N, Provenzano C, Marino M, Zoli A, Bartoccioni E (2003) Effect of pro-inflammatory/anti-inflammatory agents on cytokine secretion by peripheral blood mononuclear cells in rheumatoid arthritis and systemic lupus erythematosus. Autoimmunity 36:71–77
Hill N, Sarvetnick N (2002) Cytokines: promoters and dampeners of autoimmunity. Curr Opin Immunol 14:791–797
Sung YK, Park BL, Shin HD, Kim LH, Kim SY, Bae SC (2006) Interleukin-10 gene polymorphisms are associated with the SLICC/ACR Damage Index in systemic lupus erythematosus. Rheumatology (Oxford) 45:400–404
Tucci M, Calvani N, Richards HB, Quatraro C, Silvestris F (2005) The interplay of chemokines and dendritic cells in the pathogenesis of lupus nephritis. Ann N Y Acad Sci 1051:421–432
Lin L, Peng SL (2005) Interleukin-18 receptor signaling is not required for autoantibody production and end-organ disease in murine lupus. Arthritis Rheum 52:984–986
Calvani N, Richards HB, Tucci M, Pannarale G, Silvestris F (2004) Up-regulation of IL-18 and predominance of a Th1 immune response is a hallmark of lupus nephritis. Clin Exp Immunol 138:171–178
Qing X, Putterman C (2004) Gene expression profiling in the study of the pathogenesis of systemic lupus erythematosus. Autoimmun Rev 3:505–509
Schwarting A, Paul K, Tschirner S, Menke J, Hansen T, Brenner W, Kelley VR, Relle M, Galle PR (2005) Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice. J Am Soc Nephrol 16:3264–3272
Hueber W, Zeng D, Strober S, Utz PJ (2004) Interferon-alpha-inducible proteins are novel autoantigens in murine lupus. Arthritis Rheum 50:3239–3249
Gu L, Tseng SC, Rollins BJ (1999) Monocyte chemoattractant protein-1. Chem Immunol 72:7–29
Jiang Y, Beller DI, Frendl G, Graves DT (1992) Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J Immunol 148:2423–2428
Matsushima K, Larsen CG, DuBois GC, Oppenheim JJ (1989) Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med 169:1485–1490
Carr MW, Roth SJ, Luther E, Rose SS, Springer TA (1994) Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA 91:3652–3656
Dunzendorfer S, Kaneider NC, Kaser A, Woell E, Frade JM, Mellado M, Martinez-Alonso C, Wiedermann CJ (2001) Functional expression of chemokine receptor 2 by normal human eosinophils. J Allergy Clin Immunol 108:581–587
Heinemann A, Hartnell A, Stubbs VE, Murakami K, Soler D, LaRosa G, Askenase PW, Williams TJ, Sabroe I (2000) Basophil responses to chemokines are regulated by both sequential and cooperative receptor signaling. J Immunol 165:7224–7233
Loetscher P, Seitz M, Clark-Lewis I, Baggiolini M, Moser B (1996) Activation of NK cells by CC chemokines. Chemotaxis, Ca2+ mobilization, and enzyme release. J Immunol 156:322–327
Chan RW, Lai FM, Li EK, Tam LS, Chow KM, Lai KB, Li PK, Szeto CC (2007) Intrarenal cytokine gene expression in lupus nephritis. Ann Rheum Dis 66:886–892
Furutani Y, Nomura H, Notake M, Oyamada Y, Fukui T, Yamada M, Larsen CG, Oppenheim JJ, Matsushima K (1989) Cloning and sequencing of the cDNA for human monocyte chemotactic and activating factor (MCAF). Biochem Biophys Res Commun 159:249–255
Hasegawa H, Kohno M, Sasaki M, Inoue A, Ito MR, Terada M, Hieshima K, Maruyama H, Miyazaki J, Yoshie O, Nose M, Fujita S (2003) Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum 48:2555–2566
Shimizu S, Nakashima H, Masutani K, Inoue Y, Miyake K, Akahoshi M, Tanaka Y, Egashira K, Hirakata H, Otsuka T, Harada M (2004) Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice. Rheumatology (Oxford) 43:1121–1128
Shimizu S, Nakashima H, Karube K, Ohshima K, Egashira K (2005) Monocyte chemoattractant protein-1 activates a regional Th1 immunoresponse in nephritis of MRL/lpr mice. Clin Exp Rheumatol 23:239–242
Rovin BH, Song H, Birmingham DJ, Hebert LA, Yu CY, Nagaraja HN (2005) Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 16:467–473
Chan RW, Lai FM, Li EK, Tam LS, Wong TY, Szeto CY, Li PK, Szeto CC (2004) Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis. Arthritis Rheum 50:2882–2890
Tucci M, Barnes EV, Sobel ES, Croker BP, Segal MS, Reeves WH, Richards HB (2004) Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum 50:1842–1849
Liao CH, Yao TC, Chung HT, See LC, Kuo ML, Huang JL (2004) Polymorphisms in the promoter region of RANTES and the regulatory region of monocyte chemoattractant protein-1 among Chinese children with systemic lupus erythematosus. J Rheumatol 31:2062–2067
Wagrowska-Danilewicz M, Stasikowska O, Danilewicz M (2005) Correlative insights into immunoexpression of monocyte chemoattractant protein-1, transforming growth factor beta-1 and CD68+ cells in lupus nephritis. Pol J Pathol 56:115–120
Marks SD, Williams SJ, Tullus K, Sebire NJ (2008) Glomerular expression of monocyte chemoattractant protein-1 is predictive of poor renal prognosis in pediatric lupus nephritis. Nephrol Dial Transplant 23:3521–3526
Marks SD, Shah V, Pilkington C, Tullus K (2010) Urinary monocyte chemoattractant protein-1 correlates with disease activity in lupus nephritis. Pediatr Nephrol 25:2283–2288
Zoja C, Liu XH, Donadelli R, Abbate M, Testa D, Corna D, Taraboletti G, Vecchi A, Dong QG, Rollins BJ, Bertani T, Remuzzi G (1997) Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice. J Am Soc Nephrol 8:720–729
Dai C, Liu Z, Zhou H, Li L (2001) Monocyte chemoattractant protein-1 expression in renal tissue is associated with monocyte recruitment and tubulo-interstitial lesions in patients with lupus nephritis. Chin Med J (Engl) 114:864–868
Murali NS, Ackerman AW, Croatt AJ, Cheng J, Grande JP, Sutor SL, Bram RJ, Bren GD, Badley AD, Alam J, Nath KA (2007) Renal upregulation of HO-1 reduces albumin-driven MCP-1 production: implications for chronic kidney disease. Am J Physiol Renal Physiol 292:F837–F844
Hill GS, Delahousse M, Nochy D, Mandet C, Bariety J (2001) Proteinuria and tubulointerstitial lesions in lupus nephritis. Kidney Int 60:1893–1903
Kim HL, Lee DS, Yang SH, Lim CS, Chung JH, Kim S, Lee JS, Kim YS (2002) The polymorphism of monocyte chemoattractant protein-1 is associated with the renal disease of SLE. Am J Kidney Dis 40:1146–1152
Nakashima H, Akahoshi M, Shimizu S, Inoue Y, Miyake K, Ninomiya I, Igawa T, Sadanaga A, Otsuka T, Harada M (2004) Absence of association between the MCP-1 gene polymorphism and histological phenotype of lupus nephritis. Lupus 13:165–167
Ohtsuka K, Gray JD, Stimmler MM, Horwitz DA (1999) The relationship between defects in lymphocyte production of transforming growth factor-beta1 in systemic lupus erythematosus and disease activity or severity. Lupus 8:90–94
De Muro P, Faedda R, Fresu P, Masala A, Cigni A, Concas G, Mela MG, Satta A, Carcassi A, Sanna GM, Cherchi GM (2004) Urinary transforming growth factor-beta 1 in various types of nephropathy. Pharmacol Res 49:293–298
Chan RW, Lai FM, Li EK, Tam LS, Chow KM, Li PK, Szeto CC (2006) The effect of immunosuppressive therapy on the messenger RNA expression of target genes in the urinary sediment of patients with active lupus nephritis. Nephrol Dial Transplant 21:1534–1540
Wahl SM, Chen W (2005) Transforming growth factor-beta-induced regulatory T cells referee inflammatory and autoimmune diseases. Arthritis Res Ther 7:62–68
Schotte H, Willeke P, Rust S, Assmann G, Domschke W, Gaubitz M, Schluter B (2003) The transforming growth factor-beta1 gene polymorphism (G915C) is not associated with systemic lupus erythematosus. Lupus 12:86–92
Schiffer M, Schiffer LE, Gupta A, Shaw AS, Roberts IS, Mundel P, Bottinger EP (2002) Inhibitory smads and tgf-Beta signaling in glomerular cells. J Am Soc Nephrol 13:2657–2666
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Marks, S.D., Tullus, K. Autoantibodies in systemic lupus erythematosus. Pediatr Nephrol 27, 1855–1868 (2012). https://doi.org/10.1007/s00467-011-2078-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-011-2078-4